ArticleBlood2009
Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix.Journal of medicinal chemistry · 2025Article
- EXT1, Regulated by MiR-665, Promotes Cell Apoptosis via ERK1/2 Signaling Pathway in Acute Lymphoblastic Leukemia.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.PloS one · 2017Article
- TAM receptor tyrosine kinase function and the immunopathology of liver disease.American journal of physiology. Gastrointestinal and liver physiology · 2016Review
- Discovery of Mer kinase inhibitors by virtual screening using Structural Protein-Ligand Interaction Fingerprints.Bioorganic & medicinal chemistry · 2015Article
- Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.PloS one · 2015Article
- Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.Journal of hematology & oncology · 2013Article
- MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.Pigment cell & melanoma research · 2013Article
- Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Drugs · 2013Review
- Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.Leukemia · 2013Article
- Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis.American journal of hematology · 2012Article
- Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology.Oncogene · 2012Article
- Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.Cellular and molecular life sciences : CMLS · 2012Review
- Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.ACS medicinal chemistry letters · 2012Article
- Article
- TAM receptors in leukemia: expression, signaling, and therapeutic implications.Critical reviews in oncogenesis · 2011Article
- Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.British journal of haematology · 2010Review
- Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.Expert opinion on therapeutic targets · 2010Review
- GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.Experimental hematology · 2010Article
Corrections and comments
- Retraction · 2012-08-16Error in Cell Lines/Tissues · Error in Data ·
- Retracted
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 80%. However, additional changes using available drugs are unlikely to provide significant improvement in survival. New therapies are warranted given the risk of severe therapy-associated toxicities including infertility, organ damage, and secondary malignancy. Here, we report ectopic expression of the receptor tyrosine kinase Mer in pediatric B-cell ALL. Inhibition of Mer prevented Erk 1/2 activation, increased the sensitivity of B-ALL cells to cytotoxic agents in vitro by promoting apoptosis, and delayed disease onset in a mouse model of leukemia. In addition, we discovered cross-talk between the Mer and mammalian target of rapamycin (mTOR) signaling pathways. Our results identify Mer as a novel therapeutic target in ALL and suggest that inhibitors of Mer will interact synergistically with currently used therapies. This strategy may allow for dose reduction resulting in decreased toxicity and increased survival rates. Mer is aberrantly expressed in numerous other malignancies suggesting that this approach may have broad applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.